PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PIK3CA mutation	Squamous Cell Carcinoma of Head and Neck	PD1 inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) PD1 inhibitor Resistant : C3 ESMO 2022 - 3wk	PD1 inhibitor Resistant: C3 – Early Trials ESMO 2022 - 3 weeks PD1 inhibitor Resistant : C3 ESMO 2022 - 3 weeks - (New C3)
TERT mutation	Squamous Cell Carcinoma of Head and Neck	TERT mutation	Squamous Cell Carcinoma of Head and Neck	PD1 inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) PD1 inhibitor Sensitive : C3 ESMO 2022 - 3wk	PD1 inhibitor Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks PD1 inhibitor Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
Chr amplification(15)(q22.31)	Squamous Cell Carcinoma of Head and Neck	Chr amplification(15)(q22.31)	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil + docetaxel Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks (New C3) cisplatin + 5-fluorouracil + docetaxel Sensitive : C3 ESMO 2022 - 3wk	cisplatin + 5-fluorouracil + docetaxel Sensitive: C3 – Early Trials ESMO 2022 - 3 weeks cisplatin + 5-fluorouracil + docetaxel Sensitive : C3 ESMO 2022 - 3 weeks - (New C3)
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1	cisplatin + 5-fluorouracil + docetaxel Sensitive: A1 - Approval cisplatin + 5-fluorouracil + docetaxel Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	TPF Sensitive: A1 - Approval TPF Sensitive : A1	TPF Sensitive: A1 - Approval TPF Sensitive : A1
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1	cetuximab Sensitive: A1 - Approval cetuximab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1	pembrolizumab Sensitive: A1 - Approval pembrolizumab Sensitive : A1
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2	methotrexate Sensitive: A2 - Guideline methotrexate Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2	pembrolizumab Sensitive: A2 - Guideline pembrolizumab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	PD-L1 negative	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	ADX-2191 Sensitive: A2 - Guideline ADX-2191 Sensitive : A2	ADX-2191 Sensitive: A2 - Guideline ADX-2191 Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2	cetuximab Sensitive: A2 - Guideline cetuximab Sensitive : A2
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2	TPeX Sensitive: A2 - Guideline TPeX Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2	cisplatin Sensitive: A2 - Guideline cisplatin Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2	5-fluorouracil Sensitive: A2 - Guideline 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	pembrolizumab + nivolumab Sensitive: A2 - Guideline pembrolizumab + nivolumab Sensitive : A2	pembrolizumab + nivolumab Sensitive: A2 - Guideline pembrolizumab + nivolumab Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline carboplatin + 5-fluorouracil Sensitive : A2	carboplatin + 5-fluorouracil Sensitive: A2 - Guideline carboplatin + 5-fluorouracil Sensitive : A2
No biomarker	Squamous Cell Carcinoma of Head and Neck	No biomarker	Squamous Cell Carcinoma of Head and Neck	AT-406 Sensitive: B - Late Trials AT-406 Sensitive : B	AT-406 Sensitive: B - Late Trials AT-406 Sensitive : B
CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B	panitumumab Sensitive: B - Late Trials panitumumab Sensitive : B
HRAS mutation	Squamous Cell Carcinoma of Head and Neck	HRAS mutation	Squamous Cell Carcinoma of Head and Neck	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B	tipifarnib Sensitive: B - Late Trials tipifarnib Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B	pembrolizumab Sensitive: B - Late Trials pembrolizumab Sensitive : B
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	durvalumab + CP-675206 Sensitive: B - Late Trials durvalumab + CP-675206 Sensitive : B	durvalumab + CP-675206 Sensitive: B - Late Trials durvalumab + CP-675206 Sensitive : B
KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	KMT2D mutation	Squamous Cell Carcinoma of Head and Neck	durvalumab + CP-675206 Sensitive: B - Late Trials durvalumab + CP-675206 Sensitive : B	durvalumab + CP-675206 Sensitive: B - Late Trials durvalumab + CP-675206 Sensitive : B
EGFR amplification	Squamous Cell Carcinoma of Head and Neck	EGFR amplification	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
ERBB3-L	Squamous Cell Carcinoma of Head and Neck	ERBB3-L	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	CDKN2A negative	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
PTEN-H	Squamous Cell Carcinoma of Head and Neck	PTEN-H	Squamous Cell Carcinoma of Head and Neck	afatinib Sensitive: B - Late Trials afatinib Sensitive : B	afatinib Sensitive: B - Late Trials afatinib Sensitive : B
PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	PD-L1 overexpression	Squamous Cell Carcinoma of Head and Neck	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B

Squamous Cell Carcinoma of Head and Neck

Associations(252)

Associations
(252)